Sangro B, Galle PR, Kelley RK, Charoentum C, et al. Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma. J Clin Oncol 2024 May 28:JCO2301462. doi: 10.1200/JCO.23.01462.
PMID: 38805668